TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01356251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires & online virtual support group
Description: Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires & online virtual support group
Description: Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
Study: NCT01347619

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toolkit only with Web Access to Online Version
Description: NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toolkit, Periodic Audit/Feedback, Educational Messages
Description: Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Items in Arm 2 plus Academic Detailing Program
Description: This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
Study: NCT00133068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer
Description: Computer intervention only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction in financial barrier
Description: Copay only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer intervention & reduction of financial barrier
Description: computer intervention \& copay

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: No intervention
Study: NCT00679796

Intervention type: PROCEDURE
Intervention: Varicella (chickenpox) lesion sampling

Intervention type: PROCEDURE
Intervention: Varicella (chickenpox) lesion sampling
Study: NCT01155518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: intramuscular every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene
Description: thrice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intramuscular saline injections every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT02522663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24/7-telephone support
Description: ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
Study: NCT02966444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA-rich HF Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA-rich HF Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA-rich HF Meal
Study: NCT01391052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone acetate pretreatment
Description: 5 mg tablets, three times a day for 21 days for 2 menstrual cycles.

Intervention type: OTHER
Group type: OTHER
Intervention: No pretreatment
Description: LVN IUS is placed withour Norethindrone acetate pretreatment.
Study: NCT04208971

Intervention type: OTHER
Intervention: AI-enabled ECG-based Screening Tool for AF
Description: A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
Study: NCT02050893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedatives(Midazolam and Propofol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedatives(Midazolam and Propofol)
Study: NCT02153619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Grief Therapy (MCGT)
Description: MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Grief Therapy (MCGT)
Description: MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy (SP)
Description: SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires assessments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires assessments
Study: NCT00629369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra 3 mouth guard, Shock doctor mouth guard v3.0
Description: Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
Study: NCT04133688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASC
Description: mobile app

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASC
Description: mobile app
Study: NCT02557880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Application Diary
Description: Tool used to document sleep hygiene.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: Sleep hygiene counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Sleep hygiene counseling
Study: NCT04300166

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine & Humidification
Description: Wireless control of CPAP usage, adherence, leakage and humidifier usage
Study: NCT04518579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
Study: NCT00593190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gas SF6 (Sulfur Hexafluoride)
Description: ONCE
Study: NCT04635540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Brochure
Description: Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
Study: NCT01038999

Intervention type: BIOLOGICAL
Intervention: Peripheral blood biological tests
Description: A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.

Intervention type: BIOLOGICAL
Intervention: Peripheral blood biological tests
Description: A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.

Intervention type: BIOLOGICAL
Intervention: Peripheral blood biological tests
Description: A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
Study: NCT02679118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentire
Description: The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
Study: NCT02507700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal block
Description: In group P, popliteal block will be performed with ultrasound guidence.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be used to all patient's for anesthesia induction and maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be used to all patient's for anesthesia induction and maintenance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: For recognize the nerve (sciatic nerve), ultrasound will be used in group P.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Plaster cover
Description: Plaster cover will be used to control group for sham procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Bupivacaine 0.25% will be performed for popliteal block to group P.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laryngeal mask airway
Description: After anesthesia induction, laryngeal mask airway will be inserted to all patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway
Description: After anesthesia induction, laryngeal mask airway will be inserted to all patients
Study: NCT03331640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFF
Description: OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
Study: NCT01999517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nitroglycerin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Fluids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Fluids
Study: NCT01926496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate Gel, 0.015%
Description: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod Cream, 5%
Description: Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
Study: NCT03133416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP preparation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP and physiotherapy
Study: NCT01738646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02209532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PINPOINT
Description: PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PINPOINT
Description: PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
Study: NCT04241055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values affirmation exercise
Description: In the experimental values affirmation condition, participants spend 10-15 minutes completing a guided reflection regarding values that are personally important (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control exercise
Description: In the active control condition, participants spend 10-15 minutes completing a guided reflection regarding values that are not personally important but could be important to someone else (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).
Study: NCT04390204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervenions
Description: * Motor control exercises~* A supervised home self-rehabilitation program
Study: NCT02928016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal 1
Description: 20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal 2
Description: 20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal 3
Description: 20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal 4
Description: 20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal 5
Description: 20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal 6
Description: 20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
Study: NCT01166880

Intervention type: DEVICE
Intervention: Laser Speckle Imaging
Description: Laser Speckle Imaging Infant Head Blood flow
Study: NCT00974480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Redermic
Description: Cosmetic cream formulation 609637 43.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redermic
Description: Cosmetic cream formulation 609637 43.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin (Rejuva-A)
Description: Tretinoin 0.025% cream.
Study: NCT00202878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination
Description: one tablet orally daily.
Study: NCT02250703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: oral midazolam 0.5mg/kg upto maximum dose of 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
Study: NCT03008200

Intervention type: DEVICE
Intervention: ultrasound examination
Description: intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound

Intervention type: DEVICE
Intervention: ultrasound examination
Description: intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
Study: NCT01474018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-bromocriptine
Description: The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
Study: NCT02030236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Temperature reached Duration of exposure to cold.
Study: NCT04229537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: 200 mg intravenous (IV) on Day 1 of Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: 200 mg intravenous (IV) on Day 1 of Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: 200 mg intravenous (IV) on Day 1 of Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT200
Description: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT200
Description: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT200
Description: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Capecitabine and Oxaliplatin.
Study: NCT04506099

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TINS Active protocol
Description: Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham protocol
Description: Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
Study: NCT01636518

Intervention type: PROCEDURE
Intervention: Standard of Care
Description: Standard of care procedure as determined by treating physician for Atrial Fibrillation
Study: NCT02606149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Truthful information on chemotherapy risks
Description: One of two trained oncologist will meet the patient and inform him following an interview-guideline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of information